Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 37591293

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2023 Sep
First author
Özgüroğlu M

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2023 Oct;24(10):e405. doi: 10.1016/S1470-2045(23)00463-1.
    note
    Source null
    related pmid
    37797644
    relationship
    Erratum in

Authors and identifiers

  1. name
    Özgüroğlu M
    type
    Author
  2. name
    Kilickap S
    type
    Author
  3. name
    Sezer A
    type
    Author
  4. name
    Gümüş M
    type
    Author
  5. name
    Bondarenko I
    type
    Author
  6. name
    Gogishvili M
    type
    Author
  7. name
    Nechaeva M
    type
    Author
  8. name
    Schenker M
    type
    Author
  9. name
    Cicin I
    type
    Author
  10. name
    Ho GF
    type
    Author
  11. name
    Kulyaba Y
    type
    Author
  12. name
    Zyuhal K
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Özgüroğlu M
    type
    Author
  2. name
    Kilickap S
    type
    Author
  3. name
    Sezer A
    type
    Author
  4. name
    Gümüş M
    type
    Author
  5. name
    Bondarenko I
    type
    Author
  6. name
    Gogishvili M
    type
    Author
  7. name
    Nechaeva M
    type
    Author
  8. name
    Schenker M
    type
    Author
  9. name
    Cicin I
    type
    Author
  10. name
    Ho GF
    type
    Author
  11. name
    Kulyaba Y
    type
    Author
  12. name
    Zyuhal K
    type
    Author
bibliography ids
  1. nci-bib-cca07e514f54e9f653badc24
book metadata
content sha256
1ce054e3cce3b0b8e101c14f99771dd7243485d0abbac2327ba55ec782f84bfd
document type
citation
dois
  1. 10.1016/S1470-2045(23)00329-7
electronic publication date
display
2023 Aug 14
precision
day
year
2023
evidence scope
bibliographic_metadata_only
id
pubmed:37591293
immutable id
pubmed:37591293@1ce054e3cce3b0b8e101c14f99771dd7243485d0abbac2327ba55ec782f84bfd
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
9
name
The Lancet. Oncology
nlm unique id
100957246
pages
989-1001
volume
24
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2023 Oct;24(10):e405. doi: 10.1016/S1470-2045(23)00463-1.
    note
    Source null
    related pmid
    37797644
    relationship
    Erratum in
outcomes validated
false
pmid
37591293
provenance
batch id
5329a5d0877ee70ecd11
provider
NCBI PubMed ESummary
record sha256
ac2878763593c9a2a52ad5b283408dfd7ed77a1761d86f7507d84f6067f7d991
response sha256
bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
retrieved at
2026-09-09T23:48:15.763286+00:00
publication date
display
2023 Sep
precision
month
year
2023
publication types
  1. Randomized Controlled Trial
  2. Multicenter Study
  3. Clinical Trial, Phase III
  4. Journal Article
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/37591293/
title
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.

Preserved source evidence · Not medical advice